These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 9867539)

  • 1. Iron chelation with oral deferiprone in patients with thalassemia.
    Stella M; Pinzello G; Maggio A
    N Engl J Med; 1998 Dec; 339(23):1712; author reply 1713-4. PubMed ID: 9867539
    [No Abstract]   [Full Text] [Related]  

  • 2. Iron chelation with oral deferiprone in patients with thalassemia.
    Nathan DG; Weatherall DJ
    N Engl J Med; 1998 Dec; 339(23):1711-2; author reply 1713-4. PubMed ID: 9867538
    [No Abstract]   [Full Text] [Related]  

  • 3. Iron chelation with oral deferiprone in patients with thalassemia.
    Tricta F; Spino M
    N Engl J Med; 1998 Dec; 339(23):1710; author reply 1713-4. PubMed ID: 9867536
    [No Abstract]   [Full Text] [Related]  

  • 4. Oral iron chelation therapy for thalassaemia: an uncertain scene.
    Pippard MJ; Weatherall DJ
    Br J Haematol; 2000 Oct; 111(1):2-5. PubMed ID: 11091177
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major.
    Olivieri NF; Brittenham GM; McLaren CE; Templeton DM; Cameron RG; McClelland RA; Burt AD; Fleming KA
    N Engl J Med; 1998 Aug; 339(7):417-23. PubMed ID: 9700174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iron chelation with oral deferiprone in patients with thalassemia.
    Callea F
    N Engl J Med; 1998 Dec; 339(23):1710-1; author reply 1713-4. PubMed ID: 9867537
    [No Abstract]   [Full Text] [Related]  

  • 7. Iron chelation with oral deferiprone in patients with thalassemia.
    Cohen AR; Martin MB
    N Engl J Med; 1998 Dec; 339(23):1713-4. PubMed ID: 9867542
    [No Abstract]   [Full Text] [Related]  

  • 8. Iron chelation with oral deferiprone in patients with thalassemia.
    Wonke B; Telfer P; Hoffbrand AV
    N Engl J Med; 1998 Dec; 339(23):1712; author reply 1713-4. PubMed ID: 9867540
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacotherapy of iron overload in thalassaemic patients.
    Ceci A; Felisi M; De Sanctis V; De Mattia D
    Expert Opin Pharmacother; 2003 Oct; 4(10):1763-74. PubMed ID: 14521486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
    Saliba AN; El Rassi F; Taher AT
    Expert Rev Hematol; 2016; 9(2):151-68. PubMed ID: 26613264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
    Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Roughton M; Assomull R; Nair SV; Walker JM; Pennell DJ
    Circulation; 2007 Apr; 115(14):1876-84. PubMed ID: 17372174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients.
    Taher A; Sheikh-Taha M; Koussa S; Inati A; Neeman R; Mourad F
    Eur J Haematol; 2001 Jul; 67(1):30-4. PubMed ID: 11553264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Iron chelation in 1998].
    de Montalembert M
    Transfus Clin Biol; 1998 Oct; 5(5):353-6. PubMed ID: 9836396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iron chelation with oral deferiprone in patients with thalassemia.
    Grady RW; Giardina PJ
    N Engl J Med; 1998 Dec; 339(23):1712-3; author reply 1713-4. PubMed ID: 9867541
    [No Abstract]   [Full Text] [Related]  

  • 15. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
    Balocco M; Carrara P; Pinto V; Forni GL
    Am J Hematol; 2010 Jun; 85(6):460-1. PubMed ID: 20513129
    [No Abstract]   [Full Text] [Related]  

  • 16. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.
    El-Beshlawy A; Manz C; Naja M; Eltagui M; Tarabishi C; Youssry I; Sobh H; Hamdy M; Sharaf I; Mostafa A; Shaker O; Hoffbrand AV; Taher A
    Ann Hematol; 2008 Jul; 87(7):545-50. PubMed ID: 18351337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long term deferiprone chelation therapy.
    Hoffbrand VA; Wonke B
    Adv Exp Med Biol; 2002; 509():127-39. PubMed ID: 12572992
    [No Abstract]   [Full Text] [Related]  

  • 18. Monitoring and treatment of iron overload: state of the art and new approaches.
    Porter JB
    Semin Hematol; 2005 Apr; 42(2 Suppl 1):S14-8. PubMed ID: 15846580
    [No Abstract]   [Full Text] [Related]  

  • 19. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S; Pathare AV
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
    Kontoghiorghe CN; Kontoghiorghes GJ
    Drug Des Devel Ther; 2016; 10():465-81. PubMed ID: 26893541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.